PMID- 23859950
OWN - NLM
STAT- MEDLINE
DCOM- 20140303
LR  - 20160519
IS  - 1663-2826 (Electronic)
IS  - 1663-2818 (Linking)
VI  - 80
IP  - 1
DP  - 2013
TI  - Occurrence of slipped capital femoral epiphysis in children undergoing
      gonadotropin-releasing hormone agonist therapy for the treatment of central
      precocious puberty.
PG  - 64-8
LID - 10.1159/000351028 [doi]
AB  - BACKGROUND: Obesity, age and hormone imbalances including hypothyroidism and
      growth hormone deficiency and therapy, but not gonadotropin-releasing hormone
      agonist (GnRHa) therapy, have been identified as risk factors for slipped capital
      femoral epiphysis (SCFE). Five of 7 reported cases describe SCFE in children
      shortly after GnRHa therapy cessation. METHODS: We report 3 cases of SCFE that
      occurred in children on GnRHa therapy for the treatment of central precocious
      puberty (CPP) and discuss possible promoting factors. RESULTS: An otherwise
      healthy 8.75-year-old girl [body mass index (BMI) Z score +1.75] developed SCFE
      6.75 years into GnRHa therapy for idiopathic CPP. A second girl (with a history
      of acute lymphoblastic leukemia requiring total body irradiation) was 10.6 years 
      old (BMI Z score +1.06) when she developed SCFE 3.3 years into GnRHa therapy. The
      third case was an 8.75-year-old female with CPP secondary to a hypothalamic
      hamartoma (BMI Z score +1.65) who developed bilateral SCFE 5.6 years into
      therapy. CONCLUSION: Increasing evidence suggests an association between GnRHa
      therapy for CPP and the occurrence of SCFE. We suggest that a lack of adequate
      sex hormone exposure at a 'critical period' of bone formation may result in a
      weakened epiphysis that becomes susceptible to slipping. (c) 2013 S. Karger AG,
      Basel.
FAU - Inman, Mark
AU  - Inman M
AD  - Department of Pediatrics, IWK Health Centre, Dalhousie University, Halifax, N.S.,
      Canada.
FAU - Hursh, Brenden E
AU  - Hursh BE
FAU - Mokashi, Arati
AU  - Mokashi A
FAU - Pinto, Teresa
AU  - Pinto T
FAU - Metzger, Daniel L
AU  - Metzger DL
FAU - Cummings, Elizabeth A
AU  - Cummings EA
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20130713
PL  - Switzerland
TA  - Horm Res Paediatr
JT  - Hormone research in paediatrics
JID - 101525157
RN  - 33515-09-2 (Gonadotropin-Releasing Hormone)
RN  - EFY6W0M8TG (Leuprolide)
RN  - Hypothalamic hamartomas
RN  - Precocious Puberty, Central
SB  - IM
MH  - Age Determination by Skeleton
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - Gonadotropin-Releasing Hormone/*agonists
MH  - Hamartoma
MH  - Humans
MH  - Hypothalamic Diseases
MH  - Infant
MH  - Leuprolide/*adverse effects
MH  - Overweight/complications
MH  - Precursor Cell Lymphoblastic Leukemia-Lymphoma/radiotherapy
MH  - Puberty, Precocious/*drug therapy
MH  - Slipped Capital Femoral Epiphyses/*chemically induced/surgery
EDAT- 2013/07/19 06:00
MHDA- 2014/03/04 06:00
CRDT- 2013/07/18 06:00
PHST- 2013/01/10 00:00 [received]
PHST- 2013/03/28 00:00 [accepted]
PHST- 2013/07/18 06:00 [entrez]
PHST- 2013/07/19 06:00 [pubmed]
PHST- 2014/03/04 06:00 [medline]
AID - 000351028 [pii]
AID - 10.1159/000351028 [doi]
PST - ppublish
SO  - Horm Res Paediatr. 2013;80(1):64-8. doi: 10.1159/000351028. Epub 2013 Jul 13.